Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61. Epub 2011 Jun 9.

2.

Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H.

Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. Epub 2015 Jun 29.

3.

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R.

Hum Mol Genet. 2016 Mar 1;25(5):951-63. doi: 10.1093/hmg/ddv628. Epub 2016 Jan 6.

4.

Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.

Walker MD, Volta M, Cataldi S, Dinelle K, Beccano-Kelly D, Munsie L, Kornelsen R, Mah C, Chou P, Co K, Khinda J, Mroczek M, Bergeron S, Yu K, Cao LP, Funk N, Ott T, Galter D, Riess O, Biskup S, Milnerwood AJ, Stoessl AJ, Farrer MJ, Sossi V.

J Parkinsons Dis. 2014;4(3):483-98. doi: 10.3233/JPD-140344.

PMID:
25000966
5.

(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.

Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL.

Neurobiol Dis. 2014 Aug;68:190-9. doi: 10.1016/j.nbd.2014.04.021. Epub 2014 May 14.

PMID:
24830390
6.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

7.

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z.

J Neurosci. 2010 Feb 3;30(5):1788-97. doi: 10.1523/JNEUROSCI.5604-09.2010.

8.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

9.

Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.

Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, Milnerwood AJ.

Parkinsonism Relat Disord. 2015 Oct;21(10):1156-63. doi: 10.1016/j.parkreldis.2015.07.025. Epub 2015 Aug 1.

PMID:
26282470
10.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
11.

Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

Lee JW, Tapias V, Di Maio R, Greenamyre JT, Cannon JR.

Neurobiol Aging. 2015 Jan;36(1):505-18. doi: 10.1016/j.neurobiolaging.2014.07.011. Epub 2014 Jul 15.

12.

G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.

Xiao Q, Yang S, Le W.

J Neural Transm (Vienna). 2015 Dec;122(12):1645-57. doi: 10.1007/s00702-015-1438-9. Epub 2015 Aug 8.

PMID:
26253900
13.

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG.

Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9.

14.

(R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.

Weng YH, Chen CY, Lin KJ, Chen YL, Yeh TH, Hsiao IT, Chen IJ, Lu CS, Wang HL.

Exp Neurol. 2016 Jan;275 Pt 1:104-15. doi: 10.1016/j.expneurol.2015.09.001. Epub 2015 Sep 10.

PMID:
26363496
15.

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB.

J Biol Chem. 2015 Aug 7;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub 2015 Jun 15.

16.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

17.

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20.

PMID:
28336296
18.

Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation.

Isaias IU, Benti R, Goldwurm S, Zini M, Cilia R, Gerundini P, Di Fonzo A, Bonifati V, Pezzoli G, Antonini A.

Mov Disord. 2006 Aug;21(8):1144-7.

PMID:
16671078
19.

Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ.

PLoS One. 2011 Apr 6;6(4):e18568. doi: 10.1371/journal.pone.0018568.

20.

The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.

Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD.

J Neurosci. 2015 Aug 12;35(32):11190-5. doi: 10.1523/JNEUROSCI.0040-15.2015.

Supplemental Content

Support Center